Loading…
Intensity Therapeutics, Inc. is projected to rise to $5.15 by 2027, a +16% move from its current price of $4.46. INTS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.34 | $4.46 | $4.58 | -0.06% |
| May 30 | $4.29 | $4.45 | $4.62 | -0.12% |
| May 31 | $4.25 | $4.45 | $4.66 | -0.18% |
| Jun 1 | $4.22 | $4.45 | $4.69 | -0.24% |
| Jun 2 | $4.19 | $4.45 | $4.72 | -0.30% |
| Jun 3 | $4.16 | $4.44 | $4.74 | -0.35% |
| Jun 4 | $4.14 | $4.44 | $4.76 | -0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.14 | $4.44 | $4.76 | -0.41% |
| Week 2 | $4.01 | $4.42 | $4.88 | -0.82% |
| Week 3 | $3.90 | $4.40 | $4.97 | -1.23% |
| Week 4 | $3.81 | $4.39 | $5.05 | -1.64% |
| Week 5 | $3.73 | $4.37 | $5.11 | -2.05% |
| Week 6 | $3.66 | $4.35 | $5.17 | -2.45% |
| Week 7 | $3.60 | $4.33 | $5.22 | -2.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company that engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. trades as INTS and is positioned in the Healthcare sector. Its current price is $4.71 and its market capitalization is $12.73M, with a market rank of 5086. These fundamentals frame a small-cap biotechnology stock with a speculative upside potential reflected in its forecast path.
The forecast presents modest near-term upside and progressively stronger longer-term upside. For 2026 the avg price is $4.71 (min $4.58, max $5.77) with a 0% ROI and neutral sentiment. By 2033 the avg price rises to $6.22 (min $4.40, max $9.53) with a 32% ROI and bullish sentiment, while 2040 shows an avg of $9.01 and 91.2% ROI.
The 2050 forecast places the avg at $12.79 with a 171.6% ROI and bullish sentiment.
A major floor 13.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 19.5% above — a clean break opens room to run.
A major ceiling 128.7% above — clearing it would confirm fresh momentum.
Key INTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.64 | Sell | $4.61 | Sell |
| MA 10 | $4.67 | Sell | $4.70 | Sell |
| MA 20 | $4.90 | Sell | $4.87 | Sell |
| MA 50 | $5.35 | Sell | $5.53 | Sell |
| MA 100 | $6.98 | Sell | $6.74 | Sell |
| MA 200 | $7.96 | Sell | $11.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.91 | Buy |
| Stoch RSI (14) | 13.63 | Buy |
| CCI (20) | -125.45 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -12.38 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.66 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 26.89 | Buy |
| Momentum (10) | -0.42 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 4.64 | Sell |
| ADX (14) | 35.32 | Sell |
| ATR (14) | 0.09 | Info |
The near-term technical picture is neutral. RSI14 stands at 30, suggesting neither strong buying nor selling pressure at present. The 30-day sentiment is described as NEUTRAL rather than bullish or bearish.
Key moving averages show a closer resistance than support on the immediate horizon: the SMA50 is $5.43 and the SMA200 is $7.98. On a nearby terrain, the stock sits with a support level at $4.58 and a resistance level at $5.46. The 30-day price range spans from $3.95 to $5.61, highlighting limited upside in the very near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.46 | $4.46 | $5.43 | 0% | Neutral | |
| $4.10 | $5.15 | $6.85 | +16% | Neutral | |
| $4.00 | $5.16 | $7.11 | +16% | Neutral | |
| $3.87 | $5.10 | $7.23 | +14% | Neutral | |
| $3.78 | $5.09 | $7.37 | +14% | Neutral | |
| $3.50 | $4.79 | $7.09 | +7% | Neutral | |
| $3.80 | $5.29 | $7.98 | +19% | Neutral | |
| $4.18 | $5.90 | $9.05 | +32% | Bullish | |
| $4.32 | $6.19 | $9.64 | +39% | Bullish | |
| $4.69 | $6.83 | $10.78 | +53% | Bullish | |
| $5.49 | $8.52 | $14.28 | +91% | Bullish | |
| $6.98 | $12.09 | $22.13 | +171% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.46 | $4.46 | $5.24 | +0.00% |
| June 2026 | $3.72 | $4.36 | $5.24 | -2.21% |
| July 2026 | $3.57 | $4.23 | $5.14 | -3.11% |
| August 2026 | $3.59 | $4.28 | $5.26 | +1.18% |
| September 2026 | $3.55 | $4.25 | $5.27 | -0.59% |
| October 2026 | $3.40 | $4.08 | $5.10 | -3.90% |
| November 2026 | $3.40 | $4.11 | $5.16 | +0.57% |
| December 2026 | $3.54 | $4.30 | $5.43 | +4.57% |
Click any year to see its month-by-month INTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INTS price prediction for 2026 points to an average of $4.46 (low $4.46, high $5.43) — a potential gain of 0% on today's $4.46. A consolidation phase looks the most probable path here.
In 2027, INTS is projected to trade between $4.10 and $6.85, averaging $5.15 — a potential gain of +16% from today's $4.46. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
Intensity Therapeutics, Inc.'s 2028 outlook centres on $5.16, within a $4.00 to $7.11 range. That is up 0% on the projected 2027 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, INTS could reach as high as $7.23, with a base case around $5.10 and support toward $3.87 — roughly +14% from $4.46. Price action looks broadly range-bound.
Expect INTS to range from $3.78 to $7.37 through 2030. The $5.09 average target implies a +14% move from current prices. That is 0% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The INTS price prediction for 2031 points to an average of $4.79 (low $3.50, high $7.09) — a potential gain of +7% on today's $4.46. Price action looks broadly range-bound.
In 2032, INTS is projected to trade between $3.80 and $7.98, averaging $5.29 — a potential gain of +19% from today's $4.46. That is up +10% on the projected 2031 average. A consolidation phase looks the most probable path here.
Intensity Therapeutics, Inc.'s 2033 outlook centres on $5.90, within a $4.18 to $9.05 range. That is up +12% on the projected 2032 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2034, INTS could reach as high as $9.64, with a base case around $6.19 and support toward $4.32 — roughly +39% from $4.46. Buyers look set to stay in control over this stretch.
Expect INTS to range from $4.69 to $10.78 through 2035. The $6.83 average target implies a +53% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The INTS price prediction for 2040 points to an average of $8.52 (low $5.49, high $14.28) — a potential gain of +91% on today's $4.46. Buyers look set to stay in control over this stretch.
In 2050, INTS is projected to trade between $6.98 and $22.13, averaging $12.09 — a potential gain of +171% from today's $4.46. That is up +42% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INTS today (≈ 224.215247 INTS) could be worth
$2,711.25
+$1,711.25 (+171%) by 2050 · US Dollar
Based on the average projected INTS price of $12.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INTSwould be worth at today's price.
$1,000 invested in INTS on May 27, 2025 (≈ 123.839012 INTS) would be worth
$552.32
-$447.68 (-44.8%) today · 0.55× · US Dollar
Based on a INTS entry price of $8.07 vs. today's $4.46.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.63 | $963.28 | -3.7% |
| 1 month ago | $5.23 | $852.77 | -14.7% |
| 3 months ago | $7.8 | $571.79 | -42.8% |
| 6 months ago | $9.98 | $447.12 | -55.3% |
| 1 year ago | $8.07 | $552.32 | -44.8% |
| All time (2.9y) ago | $149 | $29.93 | -97.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INTS forecast.
Our base-case forecast reaches $8.90 around 2050.
Implied market cap at $8.90: $24.06M
Looking out across the multi-year horizon, the forecast shows a path of gradual appreciation with occasional acceleration into the 2030s and beyond. The 2026 forecast is $4.71 on average, with a 0% ROI and neutral sentiment, signaling a flat start. By 2033, the average price is projected to be $6.22 with a 32% ROI and bullish sentiment, followed by a 2034 forecast of $6.57 average and 39.6% ROI with bullish sentiment.
The forecast grows more pronounced into 2035 (avg $7.21, ROI 53.1%) and 2040 (avg $9.01, ROI 91.2%), both labeled bullish. By 2050, the average price is projected to $12.79 with a 171.6% ROI and bullish sentiment. These figures illustrate a long-run upside path, but they are estimates and not guarantees, subject to the usual uncertainties of biotech development and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows min $3.98, avg $5.35, max $7.76 with a ROI of 13.6% and neutral sentiment.
Forecasts show neutral sentiment through 2032, turning bullish in 2033 onward. The 2033 avg is $6.22 (ROI 32%), 2040 avg $9.01 (ROI 91.2%), and 2050 avg $12.79 (ROI 171.6%), indicating meaningful upside potential but these are estimates, not guarantees.
The 2027 forecast shows min $4.31, avg $5.42, max $7.22 with a ROI of 15.1% and neutral sentiment.
Current price is $4.71 and market cap is $12.73M, with a market rank of 5086.
The 2050 forecast shows min $7.38, avg $12.79, max $23.41 with a ROI of 171.6% and bullish sentiment.
Intensity Therapeutics, Inc. Community Discussion
0Share your Intensity Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.